B007
Phase 3Small molecule
B007 is one of 36 small molecule programs targeting Generalized Myasthenia Gravis. It is currently in Phase 3.
3
Indications
4
Total Trials
4
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
22 competitors in Membranous Nephropathy
#DrugCompanyPhaseTrials
1Cellcept
RocheApproved
Rituxan
RochePhase 3
Coumadin
AAbbott
Approved
Xarelto
WWim Janssens
Approved
Gazyva
RochePhase 3
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Phase 3
Rayos
RRoxane Laboratories
Phase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
B007
SShanghai Jiaolian Drug Research and Development Co., Ltd
Phase 3
MIL62
BBeijing Mabworks Biotech Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Membranous Nephropathy2 trials
A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.
Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 2/3·NCT06470191·216 enrolled
Pemphigus1 trial
A Clinical Study of B007 in the Treatment of Pemphigus.
Recruiting·SShanghai Jiaolian Drug Research and Development Co., Ltd·Phase 2/3·NCT06454357·132 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for B007. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details